Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography

Table 3 Patient characteristics and angiographic findings post intravitreal Ranibizumab monotherapy for A-ROP

No	GA	BW	PMA at FA	Eye	PMA of 1st IVR	PMA of 2nd IVR	Fluorescein Angiogram Findings
No	GA	BW	PMA at FA	Eye	PMA of 1st IVR	PMA of 2nd IVR	Avascular area at zone I (Y/N)	Leakage (Y/N)	Neovascularization (Y/N)
1	24 + 0	510	244	R	32 + 0	41 + 0	Y	Y	Y
1				L	32 + 0	41 + 0	Y	Y	Y
2	23 + 0	510	205	R	34 + 0	45 + 0	Y	Y	Y
2				L	34 + 0	45 + 0	Y	Y	Y
3	23 + 6	540	206	R	35 + 0	–	N	N	N
3				L	35 + 0	–	N	N	N
4	23 + 4	630	209	R	34 + 0	41 + 0	Y	N	N
4				L	34 + 0	41 + 0	Y	Y	Y

GA Gestational age, BW Birth weight (grams), PMA Post menstrual age (weeks), R right, L left, Y, yes, N no

ISSN: 2056-9920